Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

Kingjake26 May. 13 at 12:38 PM

$CADL Great new website. https://ir.candeltx.com/investor-relations

0 · Reply

wood4rdj May. 13 at 12:30 PM

$CADL New website vs. old...Overall, the new site reads less like: “We are developing an interesting viral immunotherapy platform” and more like: “We believe we have a registrational prostate cancer asset approaching commercialization.” That is probably the most important narrative change for investors following Candel Therapeutics.

0 · Reply

CO145 May. 13 at 12:27 PM

$CADL favorite new slide

0 · Reply

paladinten17 May. 13 at 12:21 PM

$CADL / wow - their new website is slick - easy to understand and lots of great pictures.

0 · Reply

Xanderzzzzzzz May. 13 at 12:19 PM

$CADL

0 · Reply

Kingjake26 May. 13 at 12:19 PM

$CADL Eight out of ten patients achieved complete pathological response at two years —significantly higher than standard radiation alone. Aglatimagene treatment was well tolerated with minimal serious side effects, preserving quality of life during treatment. FDA Fast Track and RMAT Designation granted based on results from 745 patients enrolled under Special Protocol Assessment.

0 · Reply

Kingjake26 May. 13 at 12:15 PM

$CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences-0 Excited to watch these as well

0 · Reply

stu4 May. 13 at 11:50 AM

$CADL gee GREEN …for the moment , lol, or for the day Afterall , big news RIGHT , lol …oh ya !

1 · Reply

Xanderzzzzzzz May. 13 at 11:30 AM

$CADL 👍

0 · Reply

ShadowBull3745 May. 13 at 11:28 AM

$CADL

0 · Reply

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

May 1, 2026, 4:05 PM EDT - 11 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2026, 8:05 AM EDT - 14 days ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

2026-04-20T10:42:20.000Z - 23 days ago

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-18T10:22:07.000Z - 2 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-17T12:22:09.000Z - 2 months ago

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

Mar 17, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

2026-03-13T10:45:12.000Z - 2 months ago

Candel Therapeutics price target lowered to $22 from $24 at Citi

2026-03-12T12:11:41.000Z - 2 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:01.000Z - 2 months ago

Candel Therapeutics sees cash runway into 1Q28

Mar 12, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 3, 2026, 11:50 AM EST - 2 months ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:05 AM EST - 2 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

2026-02-20T03:25:29.000Z - 2 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 2 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Feb 19, 2026, 9:40 PM EST - 2 months ago

Candel Therapeutics Announces Pricing of Public Offering

2026-02-19T22:10:17.000Z - 2 months ago

Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T21:13:42.000Z - 2 months ago

Candel Therapeutics announces $100M common stock offering

Feb 19, 2026, 4:05 PM EST - 2 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 2 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 3 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Dec 5, 2025, 11:00 AM EST - 5 months ago

Candel Therapeutics Transcript: R&D Day 2025

Nov 18, 2025, 3:00 AM EST - 6 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 4:05 PM EST - 6 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

2025-11-14T11:40:57.000Z - 6 months ago

Candel Therapeutics price target lowered to $24 from $25 at Citi

2025-11-13T13:31:40.000Z - 6 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

Nov 13, 2025, 8:25 AM EST - 6 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

2025-11-04T14:10:59.000Z - 6 months ago

Candel Therapeutics announces it will deliver three presentations at SITC

Nov 4, 2025, 9:00 AM EST - 6 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

2025-10-28T11:21:24.000Z - 7 months ago

Candel initiated with an Overweight at Stephens on differentiated pipeline

2025-10-27T20:35:14.000Z - 7 months ago

Candel Therapeutics initiated with an Overweight at Stephens

2025-10-21T10:40:56.000Z - 7 months ago

Candel Therapeutics initiated with an Outperform at LifeSci Capital

2025-10-16T12:20:35.000Z - 7 months ago

Candel Therapeutics appoints Pulendran to Candel’s RAB

Oct 16, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

2025-10-14T12:31:44.000Z - 7 months ago

Candel Therapeutics enters into $130M term loan facility

TRIN

2025-10-14T12:31:08.000Z - 7 months ago

Candel Therapeutics announces interim data from phase 1b CAN-3110 trial

2025-10-14T12:15:17.000Z - 7 months ago

Trinity Capital provides $130M in growth capital to Candel Therapeutics

TRIN

Oct 14, 2025, 8:10 AM EDT - 7 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 7 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 3, 2025, 9:05 AM EDT - 7 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:00 AM EDT - 8 months ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 2, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 13, 2025, 2:00 PM EDT - 9 months ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 11 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 1 year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 11, 2024, 8:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Study Result

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Nov 20, 2024, 4:30 AM EST - 1 year ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

Kingjake26 May. 13 at 12:38 PM

$CADL Great new website. https://ir.candeltx.com/investor-relations

0 · Reply

wood4rdj May. 13 at 12:30 PM

0 · Reply

CO145 May. 13 at 12:27 PM

$CADL favorite new slide

0 · Reply

paladinten17 May. 13 at 12:21 PM

$CADL / wow - their new website is slick - easy to understand and lots of great pictures.

0 · Reply

Xanderzzzzzzz May. 13 at 12:19 PM

$CADL

0 · Reply

Kingjake26 May. 13 at 12:19 PM

0 · Reply

Kingjake26 May. 13 at 12:15 PM

$CADL https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-present-upcoming-investor-conferences-0 Excited to watch these as well

0 · Reply

stu4 May. 13 at 11:50 AM

$CADL gee GREEN …for the moment , lol, or for the day Afterall , big news RIGHT , lol …oh ya !

1 · Reply

Xanderzzzzzzz May. 13 at 11:30 AM

$CADL 👍

0 · Reply

ShadowBull3745 May. 13 at 11:28 AM

$CADL

0 · Reply

Xanderzzzzzzz May. 13 at 11:27 AM

$CADL

1 · Reply

PapaSpiegs May. 13 at 11:16 AM

$CADL Check out the new website. Beautifully done! https://candeltx.com

0 · Reply

drizz May. 13 at 10:39 AM

$CADL if ya know ya know - coming to a theater near you this Friday!!!

0 · Reply

Xanderzzzzzzz May. 13 at 9:43 AM

$CADL

1 · Reply

Kingjake26 May. 13 at 8:39 AM

$CADL The Plenary Sessions: The absolute highest-scoring, practice-changing clinical trials and research abstracts are selected for the main Plenary Stage."Best of" Sessions: Dedicated wrap-up sessions specifically highlight the most compelling and highly rated science from across the entire event. Candel Therapeutics (CADL) did not present "last" at the 2026 American Urological Association (AUA) Annual Meeting, but it was scheduled for a high-profile presentation. The company presented new extended follow-up data from its randomized Phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer

1 · Reply

eagles155 May. 13 at 3:09 AM

$CADL $CADL We are presenting last during Friday's plenary session. These presentations build toward the most anticipated presentations and end with the highest-discussion or highest-impact study. Last year, CG Oncology (CGON) presented during this session and was viewed as a high-momentum late-stage oncology company, with BOND-003 data considered registration-quality. Go check their chart from this time last year to date =)

3 · Reply